Pipeline for New Obesity Therapies is Focus of New Report
...ide; Amylin/Lilly), exenatide LAR (Lilly/Amylin/Alkermes), exenatide + recombinant leptin (r-metHuLeptin; Amylin/Amgen), Symlin (pramlintide; Amylin), pramlintide + AC162352 (PYY 3-36; Amylin), liraglutide (NN2211; Novo Nordisk), albiglutide (GSK / Human Genome Science), PC-DAC:Exendin-4 (ConjuChem), Boc5 (SH-78...Endocrinology Panel Examines Interplay Between Diabetes and Cardiovascular Disease in New Report
...his report: metformin, Januvia/Janumet (sitagliptin; Merck), Byetta (exenatide; Lilly/Amylin), exenatide LAR (Lilly/Amylin/Alkermes), Symlin (Amylin), pramlintide + leptin (Amylin/Amgen), Galvus (vildagliptin; Novartis), alogliptin (Takeda), saxagliptin (BMS/AZ), Redona (denagliptin; GSK), liraglutide (Novo Nord...GlycoMark Blood Test Included in Global Diabetes Care Guidelines as Emerging Technology
...ion and other meetings show that GlycoMark is particularly valuable in detecting underlying treatment effects of agents such as exenatide (Byetta) and pramlintide (Symlin) which were not revealed by the gold standard hemoglobin A1C test. These findings have important implications for patient care and pharmaceuti...Pramlintide-A Boon to Restrain Fast Food Consumption
...g and the desire to eat high-fat foods and sweets. pramlintide is the synthetic form of amylin, a satiety hormone...the pancreas, which also produce insulin. pramlintide treatment reduces 24-hour caloric intake and meal ... partnership with insulin to regulate blood sugar. pramlintide is also under development as a potential drug for ...DURABLE Clinical Trial Results Show GlycoMark is Key Test for Managing Patients with Diabetes
... Additional Studies Indicate GlycoMark May Be a More Effective Monitor Than Hemoglobin A1C of Exenatide, Sitagliptin, pramlintide and Prandial Insulin Therapies in Certain Diabetic Populations SAN FRANCISCO, June 7 /PRNewswire/ -- GlycoMark, Inc. announced today r...Amylin Pharmaceuticals to Present New Data from Broad Diabetes and Obesity Programs at ADA 2007
...e presented by Jonathan Roth, Ph.D. on Monday, June 25 at 3:45 PM CT (4:45 PM ET). 6. Oral: "Sustained Weight Loss Following 1-y pramlintide Treatment as an Adjunct to Lifestyle Intervention in Obesity" will be presented by Steven Smith, M.D. on Monday, June 25 at 5:30 PM CT...FDA Approves New Drug to Treat Type I and Type II Diabetes
...es. Symlin should not be used if patients cannot tell when their blood sugar is low, have gastroparesis (slow stomach emptying), or are allergic to pramlintide acetate, metacresol, D-mannitol, acetic acid, or sodium acetate. Side effects associated with Symlin include but are not limited to nausea, vomitin...Amylin Pharmaceuticals Reports Third Quarter Financial Results
...kground of metformin therapy. Obesity Program -- Completed enrollment of a phase 2B study to evaluate different dosing combinations of pramlintide and metreleptin. The objective of this dose-ranging study is to support dose selection for phase 3, and to guide the development of a deliv...Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008
... a poster session on Monday, June 9 from 12:00 - 2:00 PM PT (3:00 - 5:00 PM ET). 2. Oral: "Enhanced Weight Loss Following Co-Administration of pramlintide with Sibutramine or Phentermine in Obese Subjects" will be presented by Louis Aronne, M.D. on Saturday, June 7 at 5:00 PM PT (8:00 PM ET). ...Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
...ion and other meetings show that GlycoMark is particularly valuable in detecting underlying treatment effects of agents such as exenatide (Byetta) and pramlintide (Symlin) which were not revealed by the gold standard hemoglobin A1C test. These findings have important implications for patient care and pharmaceuti...